Lionco Pharmaceutical Group Co.,Ltd. (SHA:603669)
China · Delayed Price · Currency is CNY 4.630
+0.070 (1.54%)
Feb 4, 2026, 3:00 PM CST
SHA:603669 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 420.36 | 369.53 | 189.31 | 281.79 | 734.89 | 1,000 |
Other Revenue | 10.25 | 10.25 | 7.52 | 7.47 | 5.43 | 0.66 |
| 430.61 | 379.78 | 196.83 | 289.26 | 740.33 | 1,001 | |
Revenue Growth (YoY) | 55.34% | 92.95% | -31.95% | -60.93% | -26.04% | -38.78% |
Cost of Revenue | 233.03 | 206.52 | 109.88 | 94.53 | 155.71 | 165.49 |
Gross Profit | 197.58 | 173.26 | 86.96 | 194.74 | 584.62 | 835.51 |
Selling, General & Admin | 237.44 | 230.78 | 213.48 | 327.1 | 513.55 | 698.76 |
Research & Development | 17.66 | 26.66 | 29.12 | 31.63 | 22.77 | 20.36 |
Other Operating Expenses | 8.36 | 4.79 | 5.02 | 6.3 | 9.61 | 13.33 |
Operating Expenses | 273.36 | 282.53 | 256.94 | 371.78 | 546.2 | 732.84 |
Operating Income | -75.78 | -109.27 | -169.99 | -177.04 | 38.42 | 102.66 |
Interest Expense | -36.31 | -27.38 | -3.71 | -5.83 | -15.51 | -11.25 |
Interest & Investment Income | 0.46 | 1.29 | 3.31 | 7.11 | 25.31 | 8.12 |
Other Non Operating Income (Expenses) | -1.03 | 26 | -0.81 | -0.31 | -2.41 | -1.63 |
EBT Excluding Unusual Items | -112.66 | -109.35 | -171.2 | -176.08 | 45.81 | 97.9 |
Impairment of Goodwill | - | - | - | -2.03 | - | - |
Gain (Loss) on Sale of Investments | -3.06 | -14.75 | -14.53 | -14.11 | 0.85 | -5.29 |
Gain (Loss) on Sale of Assets | 2.54 | -2.24 | 0.08 | 0.45 | -0.01 | -0.03 |
Asset Writedown | -20.37 | -20.41 | -4.12 | -0.01 | -0.19 | -0.37 |
Other Unusual Items | 19.02 | 19.02 | 38.82 | 2.98 | 24.03 | 87.04 |
Pretax Income | -114.53 | -127.73 | -150.95 | -188.81 | 70.48 | 179.26 |
Income Tax Expense | 3.85 | 3.03 | 0.54 | 7.06 | 4.58 | 19.19 |
Net Income | -118.38 | -130.76 | -151.5 | -195.86 | 65.9 | 160.07 |
Net Income to Common | -118.38 | -130.76 | -151.5 | -195.86 | 65.9 | 160.07 |
Net Income Growth | - | - | - | - | -58.83% | -20.60% |
Shares Outstanding (Basic) | 721 | 721 | 721 | 720 | 718 | 728 |
Shares Outstanding (Diluted) | 721 | 721 | 721 | 720 | 718 | 762 |
Shares Change (YoY) | 2.34% | - | 0.17% | 0.18% | -5.75% | 5.87% |
EPS (Basic) | -0.16 | -0.18 | -0.21 | -0.27 | 0.09 | 0.22 |
EPS (Diluted) | -0.16 | -0.18 | -0.21 | -0.27 | 0.09 | 0.21 |
EPS Growth | - | - | - | - | -57.14% | -25.00% |
Free Cash Flow | -165.85 | -119.74 | -61.01 | -109.2 | 73.69 | 64.86 |
Free Cash Flow Per Share | -0.23 | -0.17 | -0.09 | -0.15 | 0.10 | 0.09 |
Dividend Per Share | - | - | - | - | 0.100 | 0.200 |
Dividend Growth | - | - | - | - | -50.00% | -30.00% |
Gross Margin | 45.88% | 45.62% | 44.18% | 67.32% | 78.97% | 83.47% |
Operating Margin | -17.60% | -28.77% | -86.36% | -61.20% | 5.19% | 10.26% |
Profit Margin | -27.49% | -34.43% | -76.97% | -67.71% | 8.90% | 15.99% |
Free Cash Flow Margin | -38.52% | -31.53% | -30.99% | -37.75% | 9.95% | 6.48% |
EBITDA | -58.34 | -80.43 | -125.93 | -134.37 | 77.83 | 140.23 |
EBITDA Margin | -13.55% | -21.18% | -63.98% | -46.45% | 10.51% | 14.01% |
D&A For EBITDA | 17.44 | 28.84 | 44.05 | 42.67 | 39.41 | 37.56 |
EBIT | -75.78 | -109.27 | -169.99 | -177.04 | 38.42 | 102.66 |
EBIT Margin | -17.60% | -28.77% | -86.36% | -61.20% | 5.19% | 10.26% |
Effective Tax Rate | - | - | - | - | 6.49% | 10.70% |
Revenue as Reported | 430.61 | 379.78 | 196.83 | 289.26 | 740.33 | 1,001 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.